Last Update: Jul 15, 2024
Observational Study to Assess Safety and Effectiveness of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
ClinicalTrials.gov Identifier:
NCT06262919
Novartis Reference Number:CDRB436I1401
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This is a prospective, multicenter, single-arm, non-interventional and observational
J-PMS conducted by the central registration system and operated in Electronic data
capture. In the Post-Marketing Surveillance (PMS), dabrafenib and trametinib are used as the
marketed drugs. Registration of the corresponding patients is to be conducted by the
central registered system under current medical practice.

Target number of adult patient is 65 (as the number of patients in the effectiveness
analysis set).

Target number of pediatric patient is not determined. Estimated number of enrolled
patients is approximately 20 (as the number of patients in the enrolled set)

The observation period for pediatric patients will last after the start of treatment
until 8 years (planned, November 2031) after the approval of additional indications,
regardless of discontinuation of the product, in order to collect long-term information
from as many patients as possible during the reexamination period. The duration of
observation for adult patients will be 1 year after the start of treatment with the
product.

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Recruiting
90
Feb 09, 2024
Dec 31, 2031
All
6 Years - 99 Years (Child, Adult, Older Adult)

Interventions

Drug

Tafinlar/Mekinist

There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.

Eligibility Criteria

Inclusion Criteria:

1. Patients who have given written consent to cooperate in this surveillance

2. For patients aged < 18 years at the start of treatment with the product, their
legally authorized representative must have given written informed consent for
cooperation in this surveillance prior to patient enrollment.

3. Patients who start treatment with the product for BRAF-mutation-positive
advanced/recurrent solid tumors (excluding colorectal cancer) after the approval of
additional indications

Exclusion Criteria:

1. Patients who have received or are receiving a product containing the same ingredient
as the product in any other study or research than this surveillance

2. Patients with BRAF-mutation-positive malignant melanoma

3. Patients with BRAF-mutation-positive non-small cell lung cancer

4. Patients with BRAF-mutation-positive hairy cell leukemia

Novartis Investigative Site

Recruiting

Okayama city,Okayama,701-1192,Japan

Novartis Investigative Site

Recruiting

Osaka,550-0015,Japan

Novartis Investigative Site

Recruiting

Mito,Ibaraki,311-4145,Japan

Novartis Investigative Site

Recruiting

Shibuya,Tokyo,150-8308,Japan

Novartis Investigative Site

Recruiting

Kurume city,Fukuoka,830-0011,Japan

Novartis Investigative Site

Recruiting

Izumisano-city,Osaka,598-8577,Japan

Novartis Investigative Site

Recruiting

Saitama,330 8777,Japan

Novartis Investigative Site

Recruiting

Nagakute-city,Aichi,480-1195,Japan

Novartis Investigative Site

Recruiting

Morioka,Iwate,020 0066,Japan

Novartis Investigative Site

Recruiting

Shinjuku Ku,Tokyo,160-0023,Japan

Novartis Investigative Site

Recruiting

Fukuyama,Hiroshima,721-8511,Japan

Novartis Investigative Site

Recruiting

Bunkyo ku,Tokyo,113 8655,Japan

Novartis Investigative Site

Recruiting

Yamagata,990 9585,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,453-8511,Japan

Novartis Investigative Site

Recruiting

Kagoshima city,Kagoshima,890 8520,Japan

Novartis Investigative Site

Recruiting

Akita,010-8543,Japan

Novartis Investigative Site

Recruiting

Sapporo,Hokkaido,065-0033,Japan

Novartis Investigative Site

Recruiting

Bunkyo-ku,Tokyo,113-8519,Japan

Novartis Investigative Site

Recruiting

Nagoya,Aichi,464 8681,Japan

Novartis Investigative Site

Recruiting

Kochi city,Kochi,781 8555,Japan

Novartis Investigative Site

Recruiting

Kyoto,606 8507,Japan

Novartis Investigative Site

Recruiting

Amagasaki,Hyogo,660-8511,Japan

Novartis Investigative Site

Recruiting

Bunkyo-ku,Tokyo,113-8603,Japan

Novartis Investigative Site

Recruiting

Toyota,Aichi,470-0343,Japan

Novartis Investigative Site

Recruiting

Natori,Miyagi,981-1293,Japan

Novartis Investigative Site

Recruiting

Osaka,534-0021,Japan

Novartis Investigative Site

Recruiting

Kobe,Hyogo,650-0011,Japan

Novartis Investigative Site

Recruiting

Chuo ku,Tokyo,104 0045,Japan

Novartis Investigative Site

Recruiting

Daisen,Akita,014-0027,Japan

Novartis Investigative Site

Recruiting

Matsumoto,Nagano,390-8621,Japan

Novartis Investigative Site

Recruiting

Osaka,545-8586,Japan

Novartis Investigative Site

Recruiting

Kobe,Hyogo,650-0047,Japan

Novartis Investigative Site

Recruiting

Minato-ku,Tokyo,108-8639,Japan

Novartis Investigative Site

Recruiting

Fukuoka city,Fukuoka,812-8582,Japan

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+81337978748